Go to:
Comuta visibilidade da coluna esquerda
Você está em: Start > Project/Service Agreement:BBIT20

Project/Service Agreement:BBIT20

Start Approved In Progress Completed Closed

Estado ConcluídoCompleted
General Data
Code: 80334
Reference: BBIT20
Short name: BBIT20
Competitive Funding:
Does it involve businesses?: No
No. of Participating Institutions: 2
Type: Funded Project
Geographical Scope: International
Type of Action: R&TD
Programme: EIT Health - EIT Health
Funding Institution: COMISSÃO EUROPEIA
Financial Geographical Scope: International
Effective Start Date: 2021-11-30
Expected Completion Date: 2022-05-31
Effective Completion Date: 2022-05-31
Currency: EUR
Total Approved Budget: 5.000,00 EUR
Summary: Triple-negative breast cancer (TNBC) and advanced ovarian cancer are known by their poor prognosis and low survival rates. These hard-to-treat cancers display high resistance to the available therapy. Effective therapeutic options are urgently needed for these cancers.
The tumor suppressor BRCA1 has a critical role in homologous recombination (HR) DNA repair. In tumors, a functional BRCA1-mediated HR is related to therapeutic resistance, namely to platinum agents and PARP inhibitors as olaparib (approved for breast and ovarian cancer therapy). Thus, inhibition of the BRCA1-mediated HR DNA repair has emerged as an encouraging therapeutic strategy in aggressive breast and ovarian cancers.
This project provides the compound BBIT20 as the first disruptor of the BRCA1/BARD1 interaction, leading to downregulation of BRCA1 activity and subsequent HR inhibition. In vitro and in vivo pre-clinical data strongly support its advantages compared to other HR inhibitors, mainly olaparib, demonstrating its great potential as anticancer agent, either alone or in combination therapy, in the treatment of TNBC and advanced ovarian cancer. The enormous benefits that BBIT20 may bring to the personalized cancer therapy have made it worthy of the interest by the industry.
With this project, we intend to validate the antitumor activity and safety of BBIT20, in local and metastatic cancers, either alone or in combination therapy, using a patient-derived xenograft PDX) model, which is a keystone in translational cancer research, highly predicting the clinical therapeutic outcome of new drugs in patients. Importantly, due to a detailed genomic profiling of the tumor samples used in the PDX model, it is also expected to deeply characterize the genetic profile of the patients that may benefit from BBIT20 treatment. This will certainly add commercial value to BBIT20, boosting its marketing and successful clinical translation.
Scientific Context
Scientific Domain (FOS - Level 2): Medical and Health sciences

Academic fields (CORDIS - Level 5)

Mais informações There are no Academic Fields associated with the Project.


Mais informações There are no Keywords associated with the Project.
Mais informações There are no Documents associated with the Project.

Publications associated with the Project

Institutions Participating in the Project
Institution Contact Create Tab?
Name Short name Country Type Participation Name Telephone Email
Reitoria da Universidade do Porto REIT Portugal University Proponent António de Sousa Pereira
Instituto de Ciências e Tecnologias Agrárias e Agro-Alimentares ICETA Portugal RD Institute Sub-Contracted Lucília Saraiva
Budgets and Teams
Confidential Budget:

People in the Project

Mais informações There are no People associated with the Project.

Technicians in the Project

Mais informações There are no Technicians associated with the Project.
Mais informações There are no Laboratories associated with the Project.
Budgets and Teams
Confidential Budget:

People in the Project

Institution Name Short name Role Dedication (%) Contribution (%) Allocation
Start date End date
FFUP Lucilia Helena Ataíde Saraiva LHAS Researcher 2021-11-30 2022-05-31
REIT António Manuel de Sousa Pereira AMSP 2021-11-30 2022-05-31

Technicians in the Project

Mais informações There are no Technicians associated with the Project.
Mais informações There are no Laboratories associated with the Project.
Recommend this page Top
Copyright 1996-2024 © Reitoria da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z  I Guest Book
Page created on: 2024-07-23 00:01:15 | Acceptable Use Policy | Data Protection Policy | Complaint Portal